Liver MetastasesNCT07602504
China Metastatic Liver Cancer Clinical Registry Cohort Database
An observational study of Liver Metastases and Metastases to Liver, run by Anhui Provincial Hospital at 3 sites in China.
Trial summary
This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Liver Metastases, Metastases to Liver, Liver Cancer
- Type of treatment
- Surgery or procedure
- How many people
- 2,000 participants
- Where
- 3 sitesChina
- Study dates
- 1 Jun 2026to 31 May 2036
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Adult, Older adult
Study population: This registry targets adult patients with histologically or radiologically confirmed metastatic liver cancer. The population encompasses patients undergoing various standard clinical management strategies, including surgical resection, local ablation, transarterial chemoembolization (TACE), and systemic therapies (chemotherapy, targeted therapy, or immunotherapy).
Who may be able to join
- Patients with histologically or radiologically confirmed metastatic liver cancer.
- Age ≥ 18 years.
- Patients who have voluntarily signed the informed consent form.
- Patients with complete baseline clinical data.
Who cannot join
- Patients with primary liver cancer (e.g., hepatocellular carcinoma).
- Patients with other malignant tumors that may interfere with the evaluation of liver metastasis.
- Patients who have previously participated in other interventional clinical trials.
- Patients with severe cognitive disorders or communication barriers that prevent informed consent.
- Patients with incomplete or missing key clinical data.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
China3 sites, 3 recruiting
- Not yet recruiting
The First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, 230001
Zheng Lu, +86 13721179461, luzhengdr@163.com
- Recruiting
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Hefei, Anhui, 230001
Jizhou Wang, +86 13836135864, wangjoe@ustc.edu.cn
- Recruiting
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266003
Bing Han, MD PhD, hanbing@qduhospital.cn
About this study
This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. The primary objective is to establish a standardized, large-scale clinical cohort database specifically for metastatic liver cancer. By collecting comprehensive data on patient demographics, primary tumor characteristics, systemic therapies, and local interventions, this registry aims to elucidate the clinical patterns and prognostic factors of secondary liver malignancies. This database will serve as a robust platform for conducting high-quality real-world studies and advancing evidence-based clinical research in the management of metastatic liver cancer.
- Conditions
- Liver Metastases, Metastases to Liver, Liver Cancer, Neoplasms, Liver Diseases, Colorectal Cancer Metastatic
- Being tested
- Standard of Care for Metastatic Liver Cancer
- Keywords
- Liver Metastases; Metastatic Colorectal Cancer
- Medical subject headings
- Liver Neoplasms, Neoplasms, Liver Diseases, Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standard of Care for Metastatic Liver CancerProcedure or surgery
In this observational patient registry, no specific interventional procedure is assigned by the investigators. Patients included in the database receive standard clinical management and treatments for metastatic liver cancer according to current clinical guidelines and physician's discretion. These procedures may include hepatectomy, ablation, transarterial chemoembolization (TACE), systemic chemotherapy, targeted therapy, or immunotherapy. This registry aims to evaluate the real-world effectiveness and safety of these standard interventions.
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival
The time interval from the date of initial diagnosis (or date of enrollment/surgery) to the date of death from any cause.
Measured: Up to 10 years
Secondary outcomes (2)
Progression-Free Survival
Description: The time interval from the date of enrollment (or initial treatment) to the date of the first documented disease progression (local recurrence or distant metastasis) or death from any cause, whichever occurs first.
Measured: Up to 10 years
Treatment-Related Adverse Events
The incidence and severity of postoperative complications or treatment-related adverse events, graded according to the Clavien-Dindo classification (for surgical complications) or CTCAE (Common Terminology Criteria for Adverse Events) version 5.0.
Measured: Within 90 days post-treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2026
- Study start1 Jun 2026 (estimated)
- Primary completion31 May 2031 (estimated)
- Study completion31 May 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver MetastasesStudies of the same condition, open and under way.
- More trials run by Anhui Provincial HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Anhui Provincial Hospital
- Sponsor type
- Other government
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07602504
- Sponsor's protocol ID
- 2025KY534
- Status last verified
- May 2026
- First submitted
- 16 May 2026
- Last updated
- 22 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Individual participant data will not be made publicly available due to patient privacy and ethical restrictions. However, de-identified data may be shared with researchers who provide a methodologically sound proposal and have appropriate ethical approvals, subject to the approval of the study steering committee. Requests should be directed to the corresponding author.
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- China Metastatic Liver Cancer Clinical Registry Cohort Database
- ClinicalTrials.gov ID
- NCT07602504
- Acronym / sponsor ID
- 2025KY534
- Conditions
- Liver Metastases, Metastases to Liver, Liver Cancer, Neoplasms, Liver Diseases, Colorectal Cancer Metastatic
- Keywords
- Liver Metastases; Metastatic Colorectal Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- Anhui Provincial HospitalOther government
- Study start
- 1 Jun 2026 (estimated)
- Primary completion
- 31 May 2031 (estimated)
- Study completion
- 31 May 2036 (estimated)
- First posted
- 22 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. The primary objective is to establish a standardized, large-scale clinical cohort database specifically for metastatic liver cancer. By collecting comprehensive data on patient demographics, primary tumor characteristics, systemic therapies, and local interventions, this registry aims to elucidate the clinical patterns and prognostic factors of secondary liver malignancies. This database will serve as a robust platform for conducting high-quality real-world studies and advancing evidence-based clinical research in the management of metastatic liver cancer.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 10 Years
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- This registry targets adult patients with histologically or radiologically confirmed metastatic liver cancer. The population encompasses patients undergoing various standard clinical management strategies, including surgical resection, local ablation, transarterial chemoembolization (TACE), and systemic therapies (chemotherapy, targeted therapy, or immunotherapy).
Key inclusion criteria (4 listed)
- Patients with histologically or radiologically confirmed metastatic liver cancer.
- Age ≥ 18 years.
- Patients who have voluntarily signed the informed consent form.
- Patients with complete baseline clinical data.
Key exclusion criteria (5 listed)
- Patients with primary liver cancer (e.g., hepatocellular carcinoma).
- Patients with other malignant tumors that may interfere with the evaluation of liver metastasis.
- Patients who have previously participated in other interventional clinical trials.
- Patients with severe cognitive disorders or communication barriers that prevent informed consent.
- Patients with incomplete or missing key clinical data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standard of Care for Metastatic Liver CancerIn this observational patient registry, no specific interventional procedure is assigned by the investigators. Patients included in the database receive standard clinical management and treatments for metastatic liver cancer according to current clinical guidelines and physician's discretion. These procedures may include hepatectomy, ablation, transarterial chemoembolization (TACE), systemic chemotherapy, targeted therapy, or immunotherapy. This registry aims to evaluate the real-world effectiveness and safety of these standard interventions. | Procedure or surgery | – |
Primary outcome
Overall Survival
Time frame: Up to 10 years
The time interval from the date of initial diagnosis (or date of enrollment/surgery) to the date of death from any cause.
2 secondary outcomes
Progression-Free Survival
Time frame: Up to 10 years
Treatment-Related Adverse Events
Time frame: Within 90 days post-treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
- Individual participant dataSharing planned: Undecided. Individual participant data will not be made publicly available due to patient privacy and ethical restrictions. However, de-identified data may be shared with researchers who provide a methodologically sound proposal and have appropriate ethical approvals, subject to the approval of the study steering committee. Requests should be directed to the corresponding author.
Related trials for Liver Metastases
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingObservational study
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Liver Neoplasms, Primary Liver Cancer
Not yet recruitingPhase 2
SAMe in Prevention of Oxaliplatin-associated Liver Injury
Colorectal Cancer, Liver Metastases
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Recruiting
CREO - Microwave Ablation Feasibility Study
Pancreatic Cancer, Liver Cancer (Locally Advanced or Metastatic)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Liver Metastases and Metastases to Liver, run by Anhui Provincial Hospital at 3 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jizhou Wang, MD PhD (+86 13836135864, wangjoe@ustc.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (time frame: Up to 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.